By Kristina Kermanshahche, Chief Architect, Health & Life Sciences, Intel Corporation. Posted by Christine Fronczak

A few weeks ago I was at an industry conference and heard a colleague engaged in cancer research talk about personalized medicine and clinical analytics, and how these two important aspects of healthcare need to come together to benefit patient care. “We have the will to do this,” he said. “But do we have the way?”

After seeing Intel work closely with several life sciences customers and technology leaders recently, I believe we do have the way. Here are a few examples:

  • Using high performance computing, Intel and Dell are working together on the next generation of DNA analytics platforms that is breaking down barriers to data and information.
  • Working with the open source community to optimize leading genomics codes, introducing new ideas and efficiencies to the process.  Recent examples include Bowtie2 from Johns Hopkins, GATK from The Broad Institute, and ABySS from Canada’s Michael Smith Genome Sciences Centre.
  • Intel has been shoulder-to-shoulder with life science thought leaders, such as the Translational Genomics Research Institute (TGen), to accelerate scientific discoveries into actionable implementation. Close collaboration is helping everyone understand the challenges of personalized medicine and genomic sequencing, and see how technology and software optimization can help standardize and streamline the genomics pipeline.

A key takeaway from Intel’s work with the life sciences industry is watching the dramatic decrease in the amount of time needed to gather results.

Intel’s collaboration with TGen and Dell has focused on this aspect of genomic research. We optimized the analytics pipeline to the point where a sequencing test that used to take seven days to evaluate now can be done in four hours. This is hugely important because clinicians now have the ability to sequence multiple times during the course of a patient’s treatment, closely monitoring how that patient responds to the personalized protocols such as developing *** resistance, and perform any necessary treatment interventions within a clinically meaningful timeframe. For a cancer patient, this time savings could mean the difference between life and death. That is the way forward.

At the end of the day, there is little doubt that genomics research is positively impacting clinical treatments. Analyzing genomic information and incorporating the data into practice is happening now. Not five or 10 years from now, but today. This translates into actionable clinical care and leads to efficient treatment plans.

That is the way forward.

What questions do you have about genomics, personalized medicine and clinical analytics?

For additional information:

About Kristina Kermanshahche

 Kristina Kermanshahche is Chief Architect of Healthcare/Life Sciences at Intel Corporation.  Her focus area is Big Data/Analytics in Healthcare/Life Sciences, helping to drive transformation at the intersect of Next-Gen Sequencing (NGS), high performance computing (HPC), and healthcare informatics.  She works closely with customers and ecosystem partners to optimize high throughput sequencing and analytics, overcome systemic challenges faced by the industry, and deliver solutions which accelerate adoption of precision medicine worldwide.  Her twenty-five year career in software development spans nearly every industry, with an emphasis on complex distributed systems, parallelism, high availability, networking, and data analytics.